您好,请登录, 注册


当前位置: 首页 > 技术文献 > 应用文献 > 尿液挥发性有机物分析检测结直肠癌(CRC)

来源: Ramesh P. Arasaradnam et al   发布日期: 2019-10-10  访问量: 148

标签: 尿液、挥发性有机物、结直肠癌(CRC)

Detection of Colorectal Cancer (CRC) by Urinary Volatile Organic Compound Analysis

Ramesh P. Arasaradnam1,3*, Michael J. McFarlane3, Courtenay Ryan-Fisher3, Erik Westenbrink2,
Paula Hodges3, Matthew G. Thomas2,6, Samantha Chambers3, Nicola O’Connell3, Catherine Bailey3,
Christopher Harmston5, Chuka U. Nwokolo3, Karna D. Bardhan1,4, James A. Covington2

1 Clinical Sciences Research Institute, University of Warwick, Coventry, Warwickshire, United Kingdom,
2 School of Engineering, University of Warwick, Coventry,Warwickshire, United Kingdom,
3 Department of Gastroenterology, University Hospital Coventry & Warwickshire, Coventry, Warwickshire, United Kingdom,
4 Departmentof Gastroenterology, Rotherham General Hospital, Rotherham, Yorkshire, United Kingdom,
5 Department of Surgery, University Hospital Coventry and Warwickshire,Coventry, Warwickshire, United Kingdom,
6 MOAC Doctoral Training Centre, University of Warwick, Coventry, Warwickshire, United Kingdom

Colorectal cancer (CRC) is a leading cause of cancer related death in Europe and the USA. There is no universally accepted effective non-invasive screening test for CRC. Guaiac based faecal occult blood (gFOB) testing has largely been superseded by Faecal Immunochemical testing (FIT), but sensitivity still remains poor. The uptake of population based FOBt testing in the UK is also low at around 50%. The detection of volatile organic compounds (VOCs) signature(s) for many cancer subtypes is receiving increasing interest using a variety of gas phase analytical instruments. One such example is FAIMS (Field Asymmetric Ion Mobility Spectrometer). FAIMS is able to identify Inflammatory Bowel disease (IBD) patients by analysing shifts in VOCs patterns in both urine and faeces. This study extends this concept to determine whether CRC patients can be identified through non-invasive analysis of urine, using FAIMS. 133 patients were recruited; 83 CRC patients and 50 healthy controls. Urine was collected at the time of CRC diagnosis and headspace analysis undertaken using a FAIMS instrument (Owlstone, Lonestar, UK). Data was processed using Fisher Discriminant Analysis (FDA) after feature extraction from the raw data. FAIMS analyses demonstrated that the VOC profiles of CRC patients were tightly clustered and could be distinguished from healthy controls. Sensitivity and specificity for CRC detection with FAIMS were 88% and 60% respectively. This study suggests that VOC signatures emanating from urine can be detected in patients with CRC using ion mobility spectroscopy technology (FAIMS) with potential as a novel screening tool.